Aptose to Participate in Two Biotech Events in January 2022

Rhea-AI Summary

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) will participate in two key biotech events in January 2022: the H.C. Wainwright BIOCONNECT Virtual Conference (January 10-13) and the 11th Annual LifeSci Partners Corporate Access Event (January 5-7). The management team will host investor meetings at both events. Aptose focuses on developing innovative cancer therapies, with products like HM43239 and luxeptinib aimed at treating hematologic malignancies. For more details, visit www.aptose.com.

— H.C. Wainwright BIOCONNECT Virtual Conference —

— 11th Annual LifeSci Partners Corporate Access Event —

SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced that the company will participate in two separate biotech events in January 2022: the H.C. Wainwright BIOCONNECT Virtual Conference and the 11^th Annual LifeSci Partners Corporate Access Event. The Aptose management team will be hosting investor meetings during both events.

Details of the events are as follows:

Event:			H.C. Wainwright BIOCONNECT Virtual Conference
Date:			January 10-13, 2022
Time:			Presentations available starting at 7:00 a.m., ET on January 10, 2022
Webcast:			Accessible for registered conference attendees via the conference’s virtual platform.
Event:			11th Annual LifeSci Partners Corporate Access Event
Date:			January 5-7, 2022
1x1 Meeting Requests:			Register and submit 1x1 meeting requests here.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML), and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.  

For further information, please contact:

Aptose Biosciences Inc.			LifeSci Advisors, LLC
Susan Pietropaolo			Dan Ferry, Managing Director
Investor Relations			617-430-7576
201-923-2049			Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com

FAQ

What biotech events is Aptose participating in January 2022?

Aptose is participating in the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13 and the 11th Annual LifeSci Partners Corporate Access Event from January 5-7.

What is the focus of Aptose Biosciences?

Aptose Biosciences focuses on developing personalized therapies for unmet medical needs in oncology, primarily targeting hematologic malignancies.

What are the dates for the H.C. Wainwright BIOCONNECT Virtual Conference?

The H.C. Wainwright BIOCONNECT Virtual Conference will take place from January 10 to January 13, 2022.

What is the stock symbol for Aptose Biosciences?

The stock symbol for Aptose Biosciences is APTO, traded on NASDAQ.

Which products is Aptose developing for cancer treatment?

Aptose is developing HM43239 and luxeptinib, both targeting hematologic malignancies in clinical-stage trials.